SCHEDULE 13G 0002095697 XXXXXXXX LIVE Common Stock, par value $0.0001 11/06/2025 0001806952 Lyell Immunopharma, Inc. 55083R203 201 Haskins Way South San Francisco CA 94080 Rule 13d-1(c) Innovative Cellular Therapeutics Holdings Ltd b E9 1900000 0 1900000 0 1900000 N 9.8 OO Row 11 Footnote: This percentage is calculated based upon 19,296,408 Common Stock outstanding of Lyell Immunopharma, Inc. (the "Issuer") as of October 21, 2025. Lyell Immunopharma, Inc. 201 Haskins Way, South San Francisco, California, 94080 This Schedule is filed by Innovative Cellular Therapeutics Holdings Limited, a Cayman Island exempted company incorporated with limited liability. The foregoing entity is referred to as the "Reporting Person." The address for the Reporting Person is: 190 Elgin Avenue George Town, Grand Cayman KY1-9008 See Row 4 of cover page for the Reporting Person. Y The following information with respect to the ownership of the Common Stock of the Issuer by the person filing this Statement is provided as of November 6, 2025. See Row 9 of cover page for the Reporting Person. See Row 11 of cover page for the Reporting Person. See Row 5 of cover page for the Reporting Person. See Row 6 of cover page for the Reporting Person. See Row 7 of cover page for the Reporting Person. See Row 8 of cover page for the Reporting Person. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Innovative Cellular Therapeutics Holdings Ltd /s/ Lei Xiao 11/13/2025